MedTrace Logo

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

NCT00406471 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-03-14

No results posted yet for this study

Summary

The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.

Conditions

  • Ischemic Central Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab (Lucentis)

500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months

Sponsors & Collaborators

  • Greater Houston Retina Research

    lead OTHER

Principal Investigators

  • David M Brown, MD · Vitreoretinal Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406471 on ClinicalTrials.gov